RxDoctor Payments Data

Karl Chen, MD

Internal Medicine · East Brunswick, NJNPI 1982600169

Payments from drug & device makers

$11,988in general payments, 2019–2025

Across 1,050 payments — averaging $11.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$2K
  • AbbVie$2K
  • Amarin Pharma, Inc.$1K
  • Boehringer Ingelheim$861
  • Lilly USA, LLC$760
  • Johnson & Johnson$730
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$11,958100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,988 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$192,700
Medicare patients
197
Services billed
4,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$101,875
OzempicSemaglutide46$92,029
JardianceEmpagliflozin67$77,950
JanuviaSitagliptin Phosphate48$55,972
EliquisApixaban32$40,230
Janumet XrSitagliptin Phos/Metformin Hcl40$39,322
KerendiaFinerenone22$31,857
Soliqua 100-33Insulin Glargine/Lixisenatide28$22,502
Synjardy XrEmpagliflozin/Metformin Hcl14$21,841
MyrbetriqMirabegron11$14,028
VascepaIcosapent Ethyl14$12,901
LivaloPitavastatin Calcium12$9,882
Pitavastatin Calcium21$8,784
Icosapent Ethyl19$7,891
CrestorRosuvastatin Calcium13$7,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$760$101,87556 claims
Boehringer IngelheimJardiance, Synjardy Xr$861$99,79081 claims
MerckJanuvia, Janumet Xr$506$95,29588 claims
Novo NordiskOzempic$43$92,02946 claims
PfizerEliquis$435$40,23032 claims
BayerKerendia$162$31,85722 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$388$22,50228 claims
Astellas Pharma US IncMyrbetriq$14$14,02811 claims
Kowa Pharmaceuticals America, Inc.Livalo$1,742$9,88212 claims
AstraZenecaCrestor$13$7,60213 claims
AbbVieSynthroid$1,618$3,37745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →